Clinical trial · Interventional
A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors
NCT06148220CI-TRIAL-00074071unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study was to establish and optimize the \[18F\]RCCB6 and \[68Ga\]Ga-NOTA-RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in renal cancer (especially clear cell renal cell carcinoma) and lymphoma was evaluated.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
| Lymphomas | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Positron Emission Tomography | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT imaging | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- patients with renal cancer
- description
- Intravenous injection of 3.7 MBq \[0.1 mCi\]/kg of \[18F\]RCCB6 or \[68Ga\]Ga-NOTA-RCCB6 in a single dose
- interventionNames
- Radiation: [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT imaging
- type
- EXPERIMENTAL
- label
- patients with lymphoma
- description
- Intravenous injection of 3.7 MBq \[0.1 mCi\]/kg of \[18F\]RCCB6 or \[68Ga\]Ga-NOTA-RCCB6 in a single dose
- interventionNames
- Radiation: [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT imaging
Primary outcomes (1)
- measure
- Complete PET imaging
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. Be between 18 and 65 years of age and of either sex. 2. Affected with renal cancer or lymphoma confirmed by puncture or surgical pathology. 3. Informed consent must be signed in writing by the subject or his/her legal guardian or caregiver. 4. Willingness and ability to cooperate with all programs of this study. Exclusion Criteria: * Subjects meeting any of the following criteria will be excluded from the study: 1. Severe hepatic and renal insufficiency; 2. Targeted therapy prior to radiotherapy or PET/CT scan. Renal function: serum creatinine less than or equal to the upper limit of the normal range; 3. Liver function: bilirubin, AST(SGOT)/ALT(SGPT) less than or equal to the upper limit of the normal range. 4. History of serious surgery in the last month. 5. Those who have participated in other clinical trials during the same period.
References
Publications (1)
- DERIVEDZhou X, Wu Q, Zhai W, Zhang Y, Wu Y, Cao M, Wang C, Guan Y, Liu J, Xie F, Wei W. CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study. J Nucl Med. 2024 Dec 3;65(12):1891-1898. doi: 10.2967/jnumed.124.268509. PMID 39510586